Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant fibronectin is a bioengineered form of the high-molecular-weight extracellular matrix glycoprotein fibronectin, developed by JNU Biopharmaceutical Group (Jinan University Biopharmaceutical Group). It is produced using recombinant DNA technology, typically through microbial fermentation, to ensure high purity and safety compared to plasma-derived versions. Fibronectin plays a critical role in the extracellular matrix by binding to cell-surface integrin receptors, which facilitates essential cellular processes such as adhesion, migration, proliferation, and differentiation. In the context of JNU Biopharmaceutical Group's pipeline, it is positioned as a biomaterial ingredient intended for applications in skin repair, wound healing, and medical aesthetics. By mimicking the natural functions of endogenous fibronectin, the recombinant protein supports the reconstruction of the dermal matrix and accelerates tissue regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant fibronectin.